Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

By F. Innocenti, S. Undevia, L. Iyer, Peixian Chen, Soma Das, Masha Kocherginsky, T. Karrison, L. Janisch, J. Ramírez, C. Rudin and 2 more. Journal of Clinical Oncology, 2004

992 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/d8e67b7d7e5ecae4694e8b95a706ea40b0a87ce8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Magnus Ingelman-Sundberg

In Oncology

1. M. Eichelbaum
2. William E. Evans
3. Magnus Ingelman-Sundberg
4. Shufeng Zhou

Citations in the corpus

• Pharmacogenomics and individualized drug therapy. (2006, background): “Patients homozygous or heterozygous for seven TA repeats have a sevenfold higher likelihood of diarrhea and/or leukopenia with irinotecan therapy than do patients with the wild-type genotype (six TA repeats) (68, 69, 71).”